How complicated is diabetes? Jonathan Shaw

Similar documents
Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Microvascular Disease in Type 1 Diabetes

Microvascular Complications in Diabetes:

ADVANCE post trial ObservatioNal Study

Complications of Diabetes: Screening and Prevention

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why Do We Care About Prediabetes?

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

Glucose and CV disease

DR as a Biomarker for Systemic Vascular Complications

Update on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

American Academy of Insurance Medicine

Preventive Cardiology Scientific evidence

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Type 2 Diabetes. Treat to: limit complications maintain quality of life Improve survival

Diabetic Retinopathy and Neuropathy: 2018 Clinical Practice Guidelines

The Clinical Unmet need in the patient with Diabetes and ACS

Prevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine

The Diabetes Link to Heart Disease

CV Risk Management in Diabetes Mellitus

Hanyang University Guri Hospital Chang Beom Lee

ANNEX FORM TO EXAMINE THE CAUSES OF ESRD I IDENTIFICATION. 1 Record number (patient chart) Name. 1.1 Date of birth / / 1.2 Sex:

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus Type 2 Evidence-Based Drivers

Update on CVD and Microvascular Complications in T2D

Blood Pressure Monitoring in Chronic Kidney Disease

Diabetes mellitus The "diabetes epidemic, improved survival and strategies for rehabilitation

A Fork in the Road: Navigating Through New Terrain

Slide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now

Hypertension and diabetic nephropathy

How to Reduce CVD Complications in Diabetes?

Source of effectiveness data The effectiveness data were derived from a review or synthesis of completed studies.

The Burden of the Diabetic Heart

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Uric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Diabetes and Hypertension

The Metabolic Syndrome: Is It A Valid Concept? YES

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016

Gli endpoint micro-vascolari nei trial di outcome cardiovascolare

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Low carbohydrate diets- do they have a place?

Use of Real-World Data for Population Surveillance and Monitoring. Kasia Lipska, MD Yale School of Medicine November 17 th, 2018.

Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii

Cedars Sinai Diabetes. Michael A. Weber

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

MALATTIA CARDIOVASCOLARE NELL ANZIANO DIABETICO. Diabete e demenza. Enzo Manzato

Diabetes and kidney disease.

Complications of Diabetes: Screening and Prevention. Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley

DIABETES MEASURES GROUP OVERVIEW

This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both

Long-Term Care Updates

Diabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.

Diabetes Complications Recognition and Treatment

DCCT Diabetes Control & Complications Trial

The Diabetes Prevention Program: Call for Action

Chapter 37: Exercise Prescription in Patients with Diabetes

Diabetes Specific Features. Dealing with Diabetes and Depression. Diabetes Nepal Depression. Overview. Depression. Risk factors for Depression

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan

Reducing Acute and Chronic Events from Diabetes

2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016

Diabetic Nephropathy. Objectives:

Diabetes Mellitus and the Dental Healthcare Professional

23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen

Diabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013

Glycemic control a matter of life and death

Morbidity & Mortality from Chronic Kidney Disease

Macrovascular Disease in Diabetes

Clinical outcomes of HbA1c standardisation

Diabetic & Complications. Dr. A K Viswanath Consultant Diabetologist

Risk factors for microvascular and macrovascular complications in men and women with type 2 diabetes

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

The Flozins Quest for Clarity?

Diabetes and the heart: mechanisms of cardiac injury, hypertension and heart failure. SAGLB.DIA u Date of approval: November 2017

김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과

A computer simulation model for cost effectiveness analysis of mass screening for Type 2 diabetes mellitus

Control n. Patient Int. n at Baseline (n at. Int. Type Specific Intervention

Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes

HIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1

Cardiovascular Management of a Patient with Diabetes

New Paradigms of Type 2 Diabetes. From:

In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.

For more information about how to cite these materials visit

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009

Management of Cardiovascular Disease in Diabetes

Glucose Control: Does it lower CV risk?

Blood Pressure Treatment Goals

A study on clinical profile of acute coronary syndrome in type 2 diabetes mellitus patients with relevance to HbA1c

Obesity and Cancer Survivorship. Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη

Transcription:

How complicated is diabetes? Jonathan Shaw

Diabetic Complications Microvascular Complications Macrovascular Complications Diabetic Retinopathy Stroke Diabetic Nephropathy Heart Disease Diabetic Neuropathy Peripheral Vascular Disease

Diabetic Complications Microvascular Complications Macrovascular Complications Diabetic Retinopathy Stroke Diabetic Nephropathy Heart Disease Diabetic Neuropathy Others Peripheral Vascular Disease Fatty liver disease Sleep apnoea Cancer Depression Frailty Cog dysfunction

Glycaemia and cognition 4

Risk of incident Alzheimer s disease associated with diabetes Kopf. Journal of Alzheimer s Disease 16 (2009) 677 685 Slide courtesy of Prof K Anstey 5

Crane et al., NEJM 2013 2067 Participants mean age 76, followed for 6.8yrs 25.4% developed dementia Monotonic increase in risk with increase in glucose Slide courtesy of Prof K Anstey 6

Cerebral white matter networks Diabetes was associated with disruptions in the white matter network and these network abnormalities were related to slowing of information processing speed. Results were only partially explained by the presence of vascular lesions Reijmer Y D et al. Diabetes 2013;62:2112-2115 Page 7: Baker IDI Copyright 2011 American Diabetes Association, Inc.

In patients with diabetes, microstructural abnormalities of white matter tracts is related to slowing of information- processing speed White matter tracts were reconstructed from each hemisphere based on a standardized atlas (23), the SLF (A), the ILF (B), the UF (C), and the genu and splenium of the medial segment of the CC (D). Page 8: Baker IDI Reijmer Y D et al. Dia Care 2013;36:137-144

Diabetes and cancer Page 9: Baker IDI

Changing distribution of causes of death in T2 diabetes from 1997 2009 Median age at death increased from 74 to 80 Median age at CVD death increased from 75 to 82 Page 10: Baker IDI Harding. Diabetes Care. 2014; 37:2579-86

Association between diabetes and colorectal cancer incidence in case control and cohort studies. Page 11: Baker IDI All studies: RR 1.30 (1.20-1.40) Women 1.33 (1.23-1.44) 1 Men 1.29 (1.15-1.44) Larsson S C. JNCI J Natl Cancer Inst 2005;97:1679-87

Cancer risk related to diabetes in adults in Taiwan atio* Odds ra *adjusted for age, sex, hypertension, dyslipidemia, and gout Page 12: Baker IDI Lee. Metabolism (2011), doi:10.1016/j.metabol.2011.06.020

Diabetes and frailty Page 13: Baker IDI

Diabetes is associated with a 70% increased risk of mobility disability Page 14: Baker IDI Wong. Lancet D & E. 2013; 1:106-14

Diabetes is associated with an 80% increased risk ikof disability in activities i i of daily living Page 15: Baker IDI Wong. Lancet D & E. 2013; 1:106-14

Diabetes is associated with an 80% increased risk ikof disability in activities i i of daily living What is the mechanism? Uncertain, but evidence now indicates that t there are significant vascular and metabolic factors in osteoarthritis Page 16: Baker IDI Wong. Lancet D & E. 2013; 1:106-14

Are diabetic complication rates rising or falling? Page 17: Baker IDI

Improved survival on ESKD: Finland 1995-99 2000-05 Hazard ratio 1.4 1.2 1 08 0.8 0.6 0.4 0.2 0 95-99 00-05 Page 18: Baker IDI Kervinen M et al. Nephrol. Dial. Transplant. 2010;25:892-6

Falling incidence of proliferative retinopathy in type 1 DM DM onset 1965-69 1970-74 1975-79 1979-84 20-yr incidence 31.2% 30.3% 19.3% 12.5% Page 19: Baker IDI Hovind P et al. Dia Care 2003;26:1258-1264

Falling incidence of proliferative retinopathy in type 1 DM DM onset 1965-69 1970-7474 1975-79 1979-84 Later cohorts BP Rx started earlier BP lower HbA1c lower Fewer smokers Page 20: Baker IDI Hovind P et al. Dia Care 2003;26:1258-1264

Trends in Age-Standardized Rates of Diabetes-Related Complications among U.S. Adults with and without t Diagnosed Diabetes, 1990 2010. Percent reductions AMI 68% Stroke 53% Amputation 51% ESRD 28% Gregg EW et al. N Engl J Med 2014;370:1514-1523 Page 21: Baker IDI Gregg. NEJM 2014; 370:1514-23

Trends in amputation rates England national LEA incidence USA veterans risk of LEA Page 22: Baker IDI Vamos E P et al. Dia Care 2010;33:2592-2597 Tseng. Diabetes Care 34:1157 1163, 2011

Major variation in lower limb amputation rates in people with DM across USA and England USA 5-fold variation in LEA rates England 10-fold variation in LEA rates Margolis. Page Diabetes 23: Baker IDI Care 34:2363 7, 2011 Holman. Diabetologia 2012. DOI 10.1007/s00125-012-2468-6

Summary Increasing number of complications of diabetes Not clearly micro- or macro-vascular Excess risks more moderate than for classical complications Progress in reducing complication rates is starting to occur Geographic variability in outcomes remains a significant problem Page 24: Baker IDI